Investigators have announced results of a clinical trial culminating from 25 years of cardiovascular research work. The team reports a significant reduction in risk of recurrent heart attacks, strokes and cardiovascular death among participants who received a targeted anti-inflammatory drug that lowered inflammation but had no effects on cholesterol.